[go: up one dir, main page]

US2995492A - Piperidine derivatives with psychotogenic activity - Google Patents

Piperidine derivatives with psychotogenic activity Download PDF

Info

Publication number
US2995492A
US2995492A US704247A US70424757A US2995492A US 2995492 A US2995492 A US 2995492A US 704247 A US704247 A US 704247A US 70424757 A US70424757 A US 70424757A US 2995492 A US2995492 A US 2995492A
Authority
US
United States
Prior art keywords
piperidyl
hydrochloride
ethyl
glycolate
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US704247A
Inventor
John H Biel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LAKESIDE LAB Inc
LAKESIDE LABORATORIES Inc
Original Assignee
LAKESIDE LAB Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LAKESIDE LAB Inc filed Critical LAKESIDE LAB Inc
Priority to US704247A priority Critical patent/US2995492A/en
Application granted granted Critical
Publication of US2995492A publication Critical patent/US2995492A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5

Definitions

  • novel compounds of the formula and nontoxic acid addition salts thereof wherein R is a lower alkyl group, aralkyl groups such as benzyl", phenethyl, chlorobenzyl, methoxyphenethyl, trimethoxyphenylpropyl and p-aminophenylethyl, and aralkenyl groups such as cinnamyl, and R and R are phenyl, cycloalkyls such as cyclohexyl and cyclopentyl or thienyl groups.
  • N-methyl-3-piperidyl benzilate hydrochloride and N-ethyl-S-piperidyl benzilate hydrochloride induced distinct auditory and visual hallucinations within one hour in each individual and these recurred periodically for periods up to -10 hours after the administration of the compound.
  • the hallucinations were accompanied by gross distortions of visual images and severe alterations in feeling state.
  • Some of the subjects exhibited paranoid and megalomanic delusions, while the affective states ranged from a feeling of unpleasantness to extreme terror.
  • the compounds of this invention produce a state in humans closely approaching schizophrenia. Ceruloplasmin determinations were made on humans given N-methyl or N-ethyl-3-piperidyl benzilate hydrochloride since this enzyme was known to be increased in the serum of acute schizophrenics. Observations indicated that as much as a 50-75% elevation in the blood ceruloplasrnin accompanies the hallucinatory episode produced by these agents. Ceruloplasmin increased only when marked psychogenic disturbances were apparent and returned to normal shortly after the psychogenic effects disappeared.
  • the artificial production of hallucinations and the schizophrenia-like syndrome by the compounds provided by this invention can be, and is, being used by the psychiatrist in his study of these conditions.
  • By being able to quickly induce these conditions in an animal or human it is possible to screen agents to discover those which are antidotes and block the conditions and can be used in psychotherapeutic treatment.
  • the hallucinations produced in humans by N-methyl or N-ethyl-3-piperidyl benzilate hydrochloride and N-ethyl-3-piperidyl phenylcyclohexyl glycolate hydrochloride can be blocked by 4-hydroxyethyl-piperazinoethyl benzilate hydrochloride and that this compound possesses psychotherapeutic properties.
  • the 4-hydroxyethyl piperazinoethyl benzilate hydrochloride produced a marked beneficial effect in all disturbed schizophrenic patients to whom it was given.
  • Psychomotor epileptics who were actively hallucinating when treated with this compound partly or almost completely lost evidence of hallucinations.
  • Humans with ulcers, spastic colitis and hypertension that exhibited psychogenic disturbances have also responded effectively to 4-hydroxyethyl piperazinoethyl benzilate hydrochloride. Four or five 20 mgm. doses daily are entirely adequate for these purposes.
  • the compounds of this invention are also useful in the shocklike treatment of mental diseases or psychocatharsis produced by the psychoanalyst. Patients in whom an intense hallucinatory state is induced by these substances have shown a considerable improvement over their previous condition.
  • the compounds of this invention are conveniently prepared by reacting an N-lower alkyl-3-halopiperidine with a compound of the formula to produce the desired compound of the formula ()H R1 i wherein R, R and R have the significance previously assigned.
  • Some 3-halopiperidines which may be used in this proccss are N-methyl-3-chloropiperidine, N-ethyl-3-chloropiperidine, N-propyl-3-bromopiperidine and N-methyl- 3-bromopiperidine, N-phenethyl-3-chloropiperidine, N-paminophenethyl-3-chloropiperidine and the like.
  • Some of the other reactants which may be employed in the process are benzilic acid, phenylcyclohexyl glycolic acid, dicyclohexyl glycolic acid, phenylcyclopentyl glycolic acid and phenyl' 2-thienyl glycolic acid.
  • the reaction is conveniently effected by combining the reactants in a suitable inert liquid reaction medium, such as isopropanol, and refluxing the mixture. After filtering' and concentrating the reaction mixture in vacuo it is added to water, acidified and the unreacted acid removed with ether. After neutralizing the aqueous layer, the product is extracted with ether and the solution dried. After removing the ether the free base is obtained by vacuum distillation.
  • a suitable inert liquid reaction medium such as isopropanol
  • Acid addition salts of the tertiary bases provided by this invention are readily produced by contacting the free base with a suitable acid in the presence of a solvent such as acetone, benzene, ethanol, isopropanol and ether.
  • Typical acids which may be used are hydrochloric acid, sulfuric acid, citric acid, tartaric acid, succinic acid and benzoic acid.
  • N-ethyl-chloropipieridine was prepared according to the method of Fuson and Zirkle described in volume 70, J. Am. Chem. Soc., page 2760.
  • N-ethyd-B-chloropiperidine 12.0 grams (0.081 mole) of N-ethyd-B-chloropiperidine was mixed with 18.6 g. (0.081 mole) of benzilic acid and 80 cc. of anhydrous isopropyl alcohol as a solvent. The mixture was refluxed for seventy-two hours. The solution was then filtered and concentrated at 30 mm. of mercury. The concentrate was dissolved in water, acidified. with hydrochloric acid and extracted with ether to remove the unreacted benzilic acid.
  • the aqueous layer was neutralized with sodium bicarbonate and the product was extracted with ether.
  • the ethereal solution of the product was dried with potassium carbonate, the ether was removed by distillation and the residue was distilled at 0.120.18 mm. of mercury, the boiling point being 194-198 C. Ayield of 16.5 g. of the compound was obtained.
  • the hydrochloride salt was prepared by the addition of ethereal hydrochloric acid solution to an acetone solution of the base.
  • the white, crystalline precipitate was removed by filtration, yield' 25 g. (94%); M.P. 213- 215 C.
  • the aqueous layer was separated, made alkaline with 20% sodium hydroxide and again extracted with ether.
  • the ether extract was-dried over anhydrous potassium carbonate at room temperature, filtered, and the ether removed by distillation at 35 C. Any low boiling materials were removed by distillation at a pressure reduced to 0.3 Hg and at an oil bath temperature of 170 C.
  • the residue' was dissolved in acetone 'and acidified with 9.6 cc. of 3.77 M ethereal hydrochloric acid.
  • a white precipitate formed whichwas filtered, washed with acetone and dried at 80 C.
  • a yield of 11.0 g. (82% of theoretical) was obtained; MEP. of the product was 205207 C. After recrystallization from isopropyl alcohol, the compound melted at 206-208 C.
  • the compound was obtained in 18% yield and had a melting point of 181-182" C.
  • the psychotogens of this invention may be administered to animals and humans as pure compounds. It is advisable, however, to first combine one or more of the compounds with a suitable pharmaceutical carrier to attain a more satisfactory size to dosage relationship.
  • compositions which are liquid or solid may be used.
  • the preferred liquid carrier is water. Flavoring materials may be included in the solutions as desired.
  • Solid pharmaceutical carriers such as starch, sugar, talc, and the like, may be used to form powders.
  • the powders may be used as such or be tableted, or be used to fill gelatin capsules.
  • Suitable lubricants like magnesium stearate, binders such as gelatin and disintegrating agents like sodium carbonate in combination with citric acid may be used to form the tablets.
  • Unit dosage forms such as tablets and capsules may contain any suitable predetermined amount of one or more of the psychotogens and may be administered one or more at a time at regular intervals. Such forms should, however, generally contain a minimum concentration of 0.1% to 10% by weight of the psychotogen.
  • a typical tablet may have the composition:
  • N-methyl-S-piperidyl benzilate hydroch1oride 10 (2) Starch, U.S.P 57 (3) Lactose, U.S.P 1 73 (4) Talc, U.S.P 9 (5) Stearic acid 6 Powders 1, 2 and 3 are slugged, then granulated, nixed with 4 and 5, and tableted.
  • Tablets may also be made of the following ingredients from the stated quantities:
  • the most active compound appears to be N-ethyl-3- piperidyl phenylcyclohexyl glycolate hydrochloride and it is effective at a total dose of 2 to 5 mgm. orally.
  • the other psychotogens produce the stated efiects in doses ranging from 5 to 20 mgm. orally The duration of such effects vary from a minimum of a few hours for N- methyl-S-piperidyl phenyl-Z-thienyl glycolate. hydrochloride to over 24 hours in the case of N-ethyl-3- piperidyl phenylcyclohexyl glycolate hydrochloride.
  • psychotogens means compounds or compositions which induce, supplement, or amplify in humans and animals a state comparable or similar to the manifestations observed in a diseased mind.
  • Psychotogenie is the adjective form of psychotogens.
  • the nontoxic acid addition salts of N-Io wer alkyl- 3-piperidyl phenylcyclohexyl glycolates.
  • a pharmaceutical tablet containing a nontoxic acid addition salt of N-methyl-3-piperidyl phenylcyclopentyl glycolate 8.
  • a pharmaceutical tablet containing a nontoxic acid addition salt of N-ethyl-S-pipcridyl phenylcyclohexyl glycolate 10.
  • a pharmaceutical composition comprising a nontoxic acid addition salt of a compound of the formula enemas wherein R is a member of the group consisting oflower alkyl, pheuyl-lower alkyl and phcnyl-lower alkenyl, R is a member of the group consisting of phenyl, cycloalkyl and thienyl and R is" a member of the group consisting of cycloalkyl and thienyl but is not thienyl when R is phenyl, and in inert pharmaceutical carrier.
  • column 6, line 3-4 for "nixed” read mixed line 64, after “orally” insert a period; column 8, line 6, for “in” read an line 34, for "2,553,002” read 2,533,002 same column 8, line 35, for "Steinbach” read Sternloach Signed and sealed this 2nd day of January 1962..

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Description

United States Patent N0 Drawing. Filed Dec. 23, 1957, Ser. No. 704,247 18 Claims. (Cl. 167- 65) This invention relates to piperidine derivatives. More particularly, this invention is concerned with novel N- alkyl-3-piperidyl glycolates, methods of preparing such compounds, and uses of such compounds.
This application is a continuation-in-part of my copending application Serial No. 217,413, filed March 24, 1951, which is in turn a continuation-in-part of my copending application Serial No. 180,295, filed August 18, 1950; and is also a continuation-in-part of my copending application Serial No, 321,745, filed November 20, 1952, all now abandoned.
According to one aspect of the present invention there are provided novel compounds of the formula and nontoxic acid addition salts thereof, wherein R is a lower alkyl group, aralkyl groups such as benzyl", phenethyl, chlorobenzyl, methoxyphenethyl, trimethoxyphenylpropyl and p-aminophenylethyl, and aralkenyl groups such as cinnamyl, and R and R are phenyl, cycloalkyls such as cyclohexyl and cyclopentyl or thienyl groups. Some of the specific compounds within the scope of this invention are N-methyl-3-piperidyl benzilate,N-ethyl-3- piperidyl benzilate, N-propyl-B-piperidyl benzilate, N- methyl-3-piperidyl phenylcyclohexyl glycolate, N-ethyl- 3-piperidyl phenylcyclohexyl glycolate, N-methyl-S-piperidyl dicyclohexyl glycolate, N-ethyl-3-piperidyl dicyclohexyl glycolate, N-methyl-3-piperidyl phenyl-Z-thienyl glycolate, N-methyl-3-piperidyl phenylcyclopentyl glycolate, N-ethyl-3-piperidyl phenyleyclopentyl glycolate, N-ethyl-3-piperidyl phenyI-Z-thienyl glycolate, and nontoxic acid addition salts thereof including the hydrochloride, sulfate, maleate, fumarate, succinate, phosphate, benzoate and tartrate.
These compounds, as nontoxic acid addition salts, are powerful psychotogens.
In humans, N-methyl-S-piperidyl benzilate hydrochloride, N-ethyl-3-piperidyl benzilate hydrochloride, N-ethyl- 3-piperidyl phenylcyclohexyl glycolate hydrochloride, N-methyl-3-piperidyl phenylcyclopentyl glycolate hydrochoride, and N-methyl-3-piperidyl phenyl 2-thienyl glycolate hydrochloride have been found to be extremely powerful hallucinogens. When administered in -15 mg. doses orally to human volunteers N-methyl-3-piperidyl benzilate hydrochloride and N-ethyl-S-piperidyl benzilate hydrochloride induced distinct auditory and visual hallucinations within one hour in each individual and these recurred periodically for periods up to -10 hours after the administration of the compound. The hallucinations were accompanied by gross distortions of visual images and severe alterations in feeling state. Some of the subjects exhibited paranoid and megalomanic delusions, while the affective states ranged from a feeling of unpleasantness to extreme terror.
Humans to whom 20 mgm. of N-methyl-3-piperidyl benzilate hydrochloride and N-ethyl-3-piperidyl benzilate 2,995,492 Patented Aug. 8 1961 hydrochloride were given orally were in complete loss of contact with the environment for many hours while experiencing dramatic visual and auditory hallucinations. Animals such as cats and rodents which received these agents showed marked behavioral changes such as initial excitement and marked hyperactivity, spontaneous squealing, lack of responsiveness to stimuli, muscular weakness and lethargy.
Surprisingly, similar compounds without the hydroxyl group, such as N-ethyl-3-piperidyl diphenylacetate hydrochloride, are lacking in hallucinogenic properties. Furthermore, quaternary salts such as N-methyl-3-piperidyl benzilate methobromide orally administered do not induce hallucinations.
The compounds of this invention produce a state in humans closely approaching schizophrenia. Ceruloplasmin determinations were made on humans given N-methyl or N-ethyl-3-piperidyl benzilate hydrochloride since this enzyme was known to be increased in the serum of acute schizophrenics. Observations indicated that as much as a 50-75% elevation in the blood ceruloplasrnin accompanies the hallucinatory episode produced by these agents. Ceruloplasmin increased only when marked psychogenic disturbances were apparent and returned to normal shortly after the psychogenic effects disappeared.
The artificial production of hallucinations and the schizophrenia-like syndrome by the compounds provided by this invention can be, and is, being used by the psychiatrist in his study of these conditions. By being able to quickly induce these conditions in an animal or human it is possible to screen agents to discover those which are antidotes and block the conditions and can be used in psychotherapeutic treatment. For example, it has been found that the hallucinations produced in humans by N-methyl or N-ethyl-3-piperidyl benzilate hydrochloride and N-ethyl-3-piperidyl phenylcyclohexyl glycolate hydrochloride can be blocked by 4-hydroxyethyl-piperazinoethyl benzilate hydrochloride and that this compound possesses psychotherapeutic properties. The 4-hydroxyethyl piperazinoethyl benzilate hydrochloride produced a marked beneficial effect in all disturbed schizophrenic patients to whom it was given. Psychomotor epileptics who were actively hallucinating when treated with this compound partly or almost completely lost evidence of hallucinations. Humans with ulcers, spastic colitis and hypertension that exhibited psychogenic disturbances have also responded effectively to 4-hydroxyethyl piperazinoethyl benzilate hydrochloride. Four or five 20 mgm. doses daily are entirely adequate for these purposes.
The compounds of this invention, such as N-methyl and N-ethyl-3-piperidyl benzilate hydrochloride, N-ethyl- B-piperidyl phenylcyclohexyl glycolate hydrochloride, N-methyl-3-piperidyl phenylcyclopentyl glycolate hydrochloride, N-methyl-B-piperidyl phenyl-Z-thienyl glycolate hydrochloride and the like, are also useful in the shocklike treatment of mental diseases or psychocatharsis produced by the psychoanalyst. Patients in whom an intense hallucinatory state is induced by these substances have shown a considerable improvement over their previous condition. Depressed and anxious patients who complained of psychogenic disorders such as hypertension, colitis and ulcers showed distinct psychogenic improvement after one or two episodes induced by the agents of this invention. In addition to the disappearance of colitis and pains due to ulcer, there was a distinct improvement in the psychological or feeling state of the individuals of nontoxic quaternary ammonium salts such as the alkyl halides like methobromide, are antispasmodics and relieve musculotropic and neurotropic spasm in animals including humans. The compounds have long duration of action and few undesirable side reactions.
The compounds of this invention are conveniently prepared by reacting an N-lower alkyl-3-halopiperidine with a compound of the formula to produce the desired compound of the formula ()H R1 i wherein R, R and R have the significance previously assigned.
Some 3-halopiperidines which may be used in this proccss are N-methyl-3-chloropiperidine, N-ethyl-3-chloropiperidine, N-propyl-3-bromopiperidine and N-methyl- 3-bromopiperidine, N-phenethyl-3-chloropiperidine, N-paminophenethyl-3-chloropiperidine and the like.
Some of the other reactants which may be employed in the process are benzilic acid, phenylcyclohexyl glycolic acid, dicyclohexyl glycolic acid, phenylcyclopentyl glycolic acid and phenyl' 2-thienyl glycolic acid.
The reaction is conveniently effected by combining the reactants in a suitable inert liquid reaction medium, such as isopropanol, and refluxing the mixture. After filtering' and concentrating the reaction mixture in vacuo it is added to water, acidified and the unreacted acid removed with ether. After neutralizing the aqueous layer, the product is extracted with ether and the solution dried. After removing the ether the free base is obtained by vacuum distillation.
Acid addition salts of the tertiary bases provided by this invention are readily produced by contacting the free base with a suitable acid in the presence of a solvent such as acetone, benzene, ethanol, isopropanol and ether. Typical acids which may be used are hydrochloric acid, sulfuric acid, citric acid, tartaric acid, succinic acid and benzoic acid.
The following examples illustrate the preparation of specific compounds within the scope of this invention.
EXAMPLE 1 N-methyI-3-piperidyl benzilate 1 /Q a Q EH:
A mixture containing 8 g. (0.06 mole) of N-methyl- 3-chloropiperidine and 13.6 g. (0.06 mole) of benzilic acid in 50 cc. of anhydrous isopropyl alcohol was refluxed for 3 days; the isopropyl alcohol was removed by distillation in vacuo, the residue treated with dilute aqueous hydrochloric acid and the aqueous acid mixture extracted repeatedly with ether. The aqueous phase was separated, madestrongly alkaline with 20% aqueous sodium hydroxide and extracted with ether. The ether extracts were dried with potassium carbonate and distilled; the product was collected at 175-176 C. (0.03 mm.); yield 11.5 g. (59%).
4 EXAMPLE 2 N-methyl-3-piperidyl benzilale hydrochloride /Q a Q EH1 The free base of Examplel was dissolved in isopropyl alcohol and the solution acidified to pH 3 with ethereal hydrochloric acid. The hydrochloride salt precipitated out on cooling, yield 25 g. (84%), MP. 212-213 C.
Analysis.Calcd. for C H CINO Cl, 9.78; N, 3.87. Found: Cl, 9.73; N, 3.76.
EXAMPLE 3 N-ethyl-3-piperidyl benzilate v 0-Zg0 i...
N-ethyl-chloropipieridine was prepared according to the method of Fuson and Zirkle described in volume 70, J. Am. Chem. Soc., page 2760.
12.0 grams (0.081 mole) of N-ethyd-B-chloropiperidine was mixed with 18.6 g. (0.081 mole) of benzilic acid and 80 cc. of anhydrous isopropyl alcohol as a solvent. The mixture was refluxed for seventy-two hours. The solution was then filtered and concentrated at 30 mm. of mercury. The concentrate was dissolved in water, acidified. with hydrochloric acid and extracted with ether to remove the unreacted benzilic acid.
The aqueous layer was neutralized with sodium bicarbonate and the product was extracted with ether. The ethereal solution of the product was dried with potassium carbonate, the ether was removed by distillation and the residue was distilled at 0.120.18 mm. of mercury, the boiling point being 194-198 C. Ayield of 16.5 g. of the compound was obtained.
EXAMPLE 4 N-ethyl-S-piperidyl benzilate hydrochloride HCL 6.4 grams of the free base from Example 3 was dissolved in acetone and ethereal hydrochloric acid added. A yield of 6.2 g. of white crystals melting at 186-187 C. was obtained.
Analysis.Calcd. for C, H ClNO,: Cl, 9.45%; N, 3.72. Found: Cl, 9.29%; N, 3.62.
EXAMPLE 5 N-ethyl-3-piperidyl phenylcyclohexyl glycolate i and its hydrochloride A mixture containing 31 g. (0.13 mole) of phenylcyclohcxyl glycolic acid, 25 g..( 0.17 mole) of N-ethyl-3-chloropipendine and cc. of dry isopropyl alcohol was refluxed for 3 days; the solvent was removed by vacuum distillation and the residue suspended-in water. The aqueous suspension was-acidified with hydrochloric acid, extracted with ether and the aqueous phase made alkaline with 12 g. of sodium hydroxide. The alkaline mixture was extracted with ether, the ether extracts dried with K CO and the ether removed by distillation. The base was distilled at l66-167 C. (0.05 mm.); yield 24 g. (53%).
The hydrochloride salt was prepared by the addition of ethereal hydrochloric acid solution to an acetone solution of the base. The white, crystalline precipitate was removed by filtration, yield' 25 g. (94%); M.P. 213- 215 C.
AnaIysis.Ca1cd. for C H C1NO Cl, 9.30; N, 3.67. Found: Cl, 9.11; N, 3.66.
EXAMPLE 6 N-ethyl-3-piperidyl-phenyl-cyclopentyl-glycolate hydrochloride g lf/Q A mixture of 12.4 g. (0.056 mole) of phenyl-cyclopentyl glycolic acid, 8.3 g. (0.056 mole) N-ethyl-3-chloropiperidine and 50 cc. of dry isopropyl alcohol, as a solvent, was refluxed for 48 hours. The solvent was then removed by distillation in vacuum of the order of 15 mm. Hg. The residue was partially dissolved in aqueous hydrochloric acid and was repeatedly extracted with ether. The aqueous layer was separated, made alkaline with 20% sodium hydroxide and again extracted with ether. The ether extract was-dried over anhydrous potassium carbonate at room temperature, filtered, and the ether removed by distillation at 35 C. Any low boiling materials were removed by distillation at a pressure reduced to 0.3 Hg and at an oil bath temperature of 170 C. The residue'was dissolved in acetone 'and acidified with 9.6 cc. of 3.77 M ethereal hydrochloric acid. A white precipitate formed whichwas filtered, washed with acetone and dried at 80 C. A yield of 11.0 g. (82% of theoretical) was obtained; MEP. of the product was 205207 C. After recrystallization from isopropyl alcohol, the compound melted at 206-208 C.
Analysis.-Calcd. for C H CINO Cl, 9.66; N, 3.81. Found: Cl, 9.61; N, 3.70.
EXAMPLE 7 N-ethyl-3-piperidyl-phenyI-Z-thimyl-glycolate hydrochloride Ooii-Z Equimolar amounts of N-ethyl-3-chloropiperidine and phenyl-2-thienyl glycolate were reacted in anhydrous isopropyl alcohol at reflux for 48 hours. The mixture was concentrated in vacuum of 15 mm. Hg. The residue was dissolved in an excess of aqueous hydrochloric acid and extracted with ether. The aqueous acid solution was neutralized with 20% aqueous sodium hydroxide solution and extracted with ether. The ether extract was dried over anhydrous potassium carbonate at room temperature, filtered and distilled to remove the ether. The basic ester was distilled, dissolved in 100 cc. of acetone and acidified with ethereal hydrochloric acid to yield a precipitate. The pgcipitate was filtered, washed with acetone and dried at 80 C.
The compound was obtained in 18% yield and had a melting point of 181-182" C.
Analysis.Calcd. for C H CINO S: Cl, 9.30%; N, 3.67%. Found: Cl, 9.19; N, 3.67%.
The psychotogens of this invention may be administered to animals and humans as pure compounds. It is advisable, however, to first combine one or more of the compounds with a suitable pharmaceutical carrier to attain a more satisfactory size to dosage relationship.
Pharmaceutical carrier's which are liquid or solid may be used. The preferred liquid carrier is water. Flavoring materials may be included in the solutions as desired.
Solid pharmaceutical carriers such as starch, sugar, talc, and the like, may be used to form powders. The powders may be used as such or be tableted, or be used to fill gelatin capsules. Suitable lubricants like magnesium stearate, binders such as gelatin and disintegrating agents like sodium carbonate in combination with citric acid may be used to form the tablets.
Unit dosage forms such as tablets and capsules may contain any suitable predetermined amount of one or more of the psychotogens and may be administered one or more at a time at regular intervals. Such forms should, however, generally contain a minimum concentration of 0.1% to 10% by weight of the psychotogen.
A typical tablet may have the composition:
Mg. (1) N-methyl-S-piperidyl benzilate hydroch1oride 10 (2) Starch, U.S.P 57 (3) Lactose, U.S.P 1 73 (4) Talc, U.S.P 9 (5) Stearic acid 6 Powders 1, 2 and 3 are slugged, then granulated, nixed with 4 and 5, and tableted.
Tablets may also be made of the following ingredients from the stated quantities:
Grams (1 N-ethyl-3 -piperidyl benzilate hydrochloride 2000 (2) Lactose, U.S.P 800 (3) Dibasic calcium phosphate, U.S.P 1527.2 (4) Starch, U.S.P 799.3 (5) Calcium stearate 56.7 (6) Gelatin solution-1.5 lb./gal.- of H 0 Lactose, U.S.P 200 Starch, U.S.P 16 Talc, U.S.P 8
The most active compound appears to be N-ethyl-3- piperidyl phenylcyclohexyl glycolate hydrochloride and it is effective at a total dose of 2 to 5 mgm. orally. The other psychotogens produce the stated efiects in doses ranging from 5 to 20 mgm. orally The duration of such effects vary from a minimum of a few hours for N- methyl-S-piperidyl phenyl-Z-thienyl glycolate. hydrochloride to over 24 hours in the case of N-ethyl-3- piperidyl phenylcyclohexyl glycolate hydrochloride. As used herein psychotogens means compounds or compositions which induce, supplement, or amplify in humans and animals a state comparable or similar to the manifestations observed in a diseased mind. Psychotogenie is the adjective form of psychotogens.
Various changes and modifications of the invention can be made and, to the extent that such variations incorpo- 7 rate the spirit of this invention, they are intended to be included within the scope of the appended claims.
What is claimed is:
1. N-methyl-3-piperidyl phcnylcyclohexyl glycolate.
2. N-ethyl-3-piperidyl phenylcyclohexyl glycolate.
3. N-ethyl-3-piperidyl phenylcyclohexyl glycolate hydrochloride.
4; N-methyl-3-piperidyl phenylcyclohexyl glycolate hydrochlon'de.
5. The nontoxic acid addition salts of N-Iower alkyl- 3-piperidyl phenylcyclohexyl glycolates.
6. N-lower alkyl-3-piperidyl phenylcycloalkyl gly olate.
7. N-lower alkyl-3-piperidyl phenylcyclopentyl glycolate.
8. N-methyl-B-piperidyl phenylcyclopentyl glycolate hydrochloride.
9. A pharmaceutical tablet containing a nontoxic acid addition salt of N-methyl-3-piperidyl phenylcyclopentyl glycolate.
10. A pharmaceutical tablet containing a nontoxic acid addition salt of N-ethyl-S-pipcridyl phenylcyclohexyl glycolate.
11. The method of inducing a psychotogenic state in humans and animals which comprises administering to and nontoxic acid addition salts thereof, wherein R is a member of the group consisting of lower alkyl, phenyllower alkyl and phenyl-lower alkenyl, R is a member of the group consisting of phenyl, cycloalkyl and thienyl and R is a member of the group consisting of cycloalkyl and thienyl but is not thienyl when R is phenyl.
16. A pharmaceutical composition comprising a nontoxic acid addition salt of a compound of the formula enemas wherein R is a member of the group consisting oflower alkyl, pheuyl-lower alkyl and phcnyl-lower alkenyl, R is a member of the group consisting of phenyl, cycloalkyl and thienyl and R is" a member of the group consisting of cycloalkyl and thienyl but is not thienyl when R is phenyl, and in inert pharmaceutical carrier.
17. A composition according to claim 16 in which the carrier is a solid.
18; The method of inducing a psychotogenicstate in humans and animals which comprises administering to them an efiective amount of a compound of the formula and nontoxic acid addition salts thereof,.wherein- R is a member of the group consisting of lower alkyl, phenyllower alkyl and phenyl-lower alkenyl, R is a member of the group consisting of phenyl, cycloalkyl and thienyl and R is a member of the group consisting of cycloalkyl and thienyl but is not thienyl when R is phenyl.
References Cited in the file of this patent UNITED STATES RATENTS 2,167,351 Eisleb July 25, 1939 2,265,185 Miescher Dec. 9, 1941 2,477,937 Paul Aug. 2, 1949 2,486,794 Miescher Nov. 1, 1949 2,553,002 Feldkamp Dec. 5, 1950 2,648,667 Steinbach Aug. 11, 1953 2,792,399 Ekenstam et al. May'14, 1957 2,816,895 Ehrhart Dec. 17, 1957 2,844,591 Feldkamp et al July 22, 1958 2,918,406 Biel Dec. 22, 1959 2,918,408 Biel Dec. 22, 1959 FOREIGN PATENTS 448,181 Great Britain May 25, 1936 483,258 Great Britain Apr. 14, 1938 OTHER REFERENCES McElvain et al.: J.A.C.S., vol. 10, pp. 1826-1828, 1948.
Biel et al.: J.A.C.S., vol. 74, pp. 1485-1488, 1952.
Richters Organic Chemistry, v01.' 13, Blakistons Son and Co., 1923, pp. 3-4.
Blicke et al.: J.A.C.S., vol. 64, February 1942, pp. 431-433.
Ford-Moore et al.: I Cheml Soc. (London), Part I, (1947), pp. -60.
' UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent N0. 2,995,492. August 8, 1961 John H. Biel It is hereby certified that error appears in the above numbered patent requiring correction and that the said Letters Patent should read as corrected below.
Column 4, line 6, right-hand portion of the formula, for HCL" read .HCl column 5, lines 58 to 60, the lower I righthand portion of the formula should appear as shown below instead of as in the patent:
column 6, line 3-4, for "nixed" read mixed line 64, after "orally" insert a period; column 8, line 6, for "in" read an line 34, for "2,553,002" read 2,533,002 same column 8, line 35, for "Steinbach" read Sternloach Signed and sealed this 2nd day of January 1962..
(SEAL) Attest: ERNEST W. SWIDER Attesting Officer DAVID L. LADD Commissioner of Patents

Claims (1)

16. A PHARMACEUTICAL COMPOSITION COMPRISING A NONTOXIC ACID ADDITION SALT OF A COMPOUND OF THE FORMULA
US704247A 1957-12-23 1957-12-23 Piperidine derivatives with psychotogenic activity Expired - Lifetime US2995492A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US704247A US2995492A (en) 1957-12-23 1957-12-23 Piperidine derivatives with psychotogenic activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US704247A US2995492A (en) 1957-12-23 1957-12-23 Piperidine derivatives with psychotogenic activity

Publications (1)

Publication Number Publication Date
US2995492A true US2995492A (en) 1961-08-08

Family

ID=24828706

Family Applications (1)

Application Number Title Priority Date Filing Date
US704247A Expired - Lifetime US2995492A (en) 1957-12-23 1957-12-23 Piperidine derivatives with psychotogenic activity

Country Status (1)

Country Link
US (1) US2995492A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3240784A (en) * 1966-03-15 Esters of quaternary z-hydroxy methyl piperidinium compounds
US3254112A (en) * 1963-05-16 1966-05-31 Philips Corp Substituted tertiary amino compounds having valuable pharmacological properties
US3381017A (en) * 1965-06-04 1968-04-30 Syntex Corp Production of carbinols employing cyclopentadienyl or lower alkyl substituted cyclopentadienyl grignard reagents and hydrogenation
WO2015181837A2 (en) 2014-05-30 2015-12-03 Sphaera Pharma Pvt. Ltd. Novel compounds as anti-tubercular agents

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB448181A (en) * 1934-07-12 1936-05-25 Chem Ind Basel Manufacture of basic esters of polyarylacetic acids
GB483258A (en) * 1936-06-08 1938-04-14 Arthur George Bloxam Manufacture of basic esters of polyarylacetic acids
US2167351A (en) * 1937-08-07 1939-07-25 Winthrop Chem Co Inc Piperidine compounds and a process of preparing them
US2265185A (en) * 1938-08-05 1941-12-09 Ciba Pharm Prod Inc Basic esters and amides and process of producing same
US2477937A (en) * 1945-01-13 1949-08-02 Rhone Poulenc Sa N-hydrocarbon 3-piperidinols
US2486794A (en) * 1943-06-25 1949-11-01 Ciba Pharm Prod Inc 1-alkyl-4-(meta-hydroxyphenyl)-piperidyl-(4)-alkylketones and their production
US2553002A (en) * 1948-11-15 1951-05-15 Hastings Mfg Co Piston ring assembly
US2648667A (en) * 1951-04-18 1953-08-11 Hoffmann La Roche Esters of 1-azabicycloalkanols
US2792399A (en) * 1954-05-29 1957-05-14 Bofors Ab Anilides of heterocyclic compounds
US2816895A (en) * 1954-11-30 1957-12-17 Hoechst Ag Basic benzilic esters and a process of preparing them
US2844591A (en) * 1955-10-14 1958-07-22 Mead Johnson & Co 1-substituted-3-pyrrolidylmethyl benzilates and salts thereof
US2918408A (en) * 1957-04-08 1959-12-22 Lakeside Lab Inc Anti-spasmodic compositions specific for treating spasm of the colon
US2918406A (en) * 1957-04-08 1959-12-22 Lakeside Lab Inc Anti-spasmodics specific for peptic ulcer

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB448181A (en) * 1934-07-12 1936-05-25 Chem Ind Basel Manufacture of basic esters of polyarylacetic acids
GB483258A (en) * 1936-06-08 1938-04-14 Arthur George Bloxam Manufacture of basic esters of polyarylacetic acids
US2167351A (en) * 1937-08-07 1939-07-25 Winthrop Chem Co Inc Piperidine compounds and a process of preparing them
US2265185A (en) * 1938-08-05 1941-12-09 Ciba Pharm Prod Inc Basic esters and amides and process of producing same
US2486794A (en) * 1943-06-25 1949-11-01 Ciba Pharm Prod Inc 1-alkyl-4-(meta-hydroxyphenyl)-piperidyl-(4)-alkylketones and their production
US2477937A (en) * 1945-01-13 1949-08-02 Rhone Poulenc Sa N-hydrocarbon 3-piperidinols
US2553002A (en) * 1948-11-15 1951-05-15 Hastings Mfg Co Piston ring assembly
US2648667A (en) * 1951-04-18 1953-08-11 Hoffmann La Roche Esters of 1-azabicycloalkanols
US2792399A (en) * 1954-05-29 1957-05-14 Bofors Ab Anilides of heterocyclic compounds
US2816895A (en) * 1954-11-30 1957-12-17 Hoechst Ag Basic benzilic esters and a process of preparing them
US2844591A (en) * 1955-10-14 1958-07-22 Mead Johnson & Co 1-substituted-3-pyrrolidylmethyl benzilates and salts thereof
US2918408A (en) * 1957-04-08 1959-12-22 Lakeside Lab Inc Anti-spasmodic compositions specific for treating spasm of the colon
US2918406A (en) * 1957-04-08 1959-12-22 Lakeside Lab Inc Anti-spasmodics specific for peptic ulcer

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3240784A (en) * 1966-03-15 Esters of quaternary z-hydroxy methyl piperidinium compounds
US3254112A (en) * 1963-05-16 1966-05-31 Philips Corp Substituted tertiary amino compounds having valuable pharmacological properties
US3381017A (en) * 1965-06-04 1968-04-30 Syntex Corp Production of carbinols employing cyclopentadienyl or lower alkyl substituted cyclopentadienyl grignard reagents and hydrogenation
WO2015181837A2 (en) 2014-05-30 2015-12-03 Sphaera Pharma Pvt. Ltd. Novel compounds as anti-tubercular agents
WO2015181837A3 (en) * 2014-05-30 2016-02-18 Sphaera Pharma Pvt. Ltd. Novel compounds as anti-tubercular agents
US10100012B2 (en) 2014-05-30 2018-10-16 Sphaera Pharma Pvt. Ltd. Compounds as anti-tubercular agents
US10207993B2 (en) 2014-05-30 2019-02-19 Sphaera Pharma Pvt. Ltd. Compounds as anti-tubercular agents

Similar Documents

Publication Publication Date Title
EP0641320B1 (en) Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists
US4721711A (en) Pyridazine derivatives active on the central nervous system, and medicaments in which they are present
US4299838A (en) Tryptophan derivatives having an increased effect on the central nervous system
IE47798B1 (en) Substituted ortho-anisamides,methods of preparing them,compositions containing them and their application as psychotropic agents
EA001534B1 (en) Derivatives of cyclic amino acid or pharmaceutically acceptable salts thereof, pharmaceutical composition and method of treatment depression, panic conditions, states of fear and pain
EA023751B1 (en) Kit, composition, product or medicament for treating cognitive impairment
US4226861A (en) N-Lower-alkyl 3-phenoxy-1-azetidinecarboxamides
US3405134A (en) Quinuclidyl esters of aromatic acids
US4514414A (en) N-Substituted pyrrolidineacetic acids and their esters
US4599355A (en) Treatment of sleep disorders
US4249021A (en) Indanacetic acid compounds
KR20030024710A (en) Substituted phthalides as anti-convulsive drugs
US2995492A (en) Piperidine derivatives with psychotogenic activity
US3637803A (en) Alkyl methylsulfonylalkyl benzoates
US4237165A (en) Treatment of carbohydrate metabolism disorders
US2807617A (en) Acylpiperazines and methods of preparing the same
JPS5935387B2 (en) Di-substituted phenol ethers of 3-amino-2-hydroxypropane, their preparation and pharmaceutical uses
US4160031A (en) Antihistaminic and appetite stimulating 10,11-dihydro-3-carboxycyproheptadine
US3141015A (en) Hgmopiperazinoalkyl estess
KR940009791B1 (en) Process for preparing quinuclidine derivatives
US3709913A (en) N-thienylalkyl-beta-alkoxy-trifluoro-methylphenalkylamines
US3278381A (en) 5 amino-1-phenyltetrazole muscle relaxant preparations
US2899358A (en) Process
US3700675A (en) Ester of 2-hydroxy-cyclohexane-2-substituted carboxylic acids
US3900563A (en) Method of using 3-(2-(4-phenyl-1-piperazinyl)ethyl)-indolines